Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

ERAS

+ Watchlist+ Portfolio

Erasca, Inc.

Regulated industryDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$13.89
52-Week Range
$2.75 – $24.28
Market Cap
$4.83B
P/E (TTM)
—
EPS (TTM)
-0.97
Dividend Yield
0.00%
Advanced Metrics
Price/Book
5.26
PEG Ratio
—
Return on Equity
-48.70%
Return on Assets
-15.65%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
14.89
Debt/Equity
0.05
Total Debt
$43.41M
Free Cash Flow
$-207.85M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$4.23B

Market Snapshot

About

Erasca, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes multiple precision oncology programs targeting specific genetic mutations common in various solid tumors, including lung, colorectal, and pancreatic cancers. Erasca's lead programs include ERAS-007, an oral ERK1/2 inhibitor, and naporafenib, a pan-RAF inhibitor being developed for RAS-mutant tumors. The company employs a precision medicine approach, developing therapies designed to target specific molecular alterations in cancer cells. Founded in 2018 and headquartered in San Diego, California, Erasca went public in 2021 through a merger with a special purpose acquisition company (SPAC).